Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations-Reference-Cited by-同舟云学术

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Published:2021-03-16 Issue:14 Volume:27 Page:3845-3853
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Adib Elio,Klonowska Katarzyna,Giannikou Krinio,Do Khanh T.,Pruitt-Thompson Solida,Bhushan Ketki,Milstein Matthew I.,Hedglin Jennifer,Kargus Katherine E.,Sholl Lynette M.^ORCID,Tsuji Junko,Hyman David M.,Sisk Anne,Shapiro Geoffrey I.,Vargas Hebert A.^ORCID,Harding James J.,Voss Martin H.^ORCID,Iyer Gopa,Kwiatkowski David J.^ORCID

Funder

Novartis Inc

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center Support Grant

Core Grant

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era;Expert Review of Molecular Diagnostics;2024-08-28

2. mTOR signaling is required for phagocyte free radical production, GLUT1 expression, and control of Staphylococcus aureus infection;mBio;2024-06-12

3. Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy;2024-05-02

4. Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy;eBioMedicine;2024-05

5. Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis;International Journal of Molecular Sciences;2024-04-25